Dr Reddys launches Valsartan in US
Hyderabad: Dr. Reddy's Laboratories Ltd. has announced the launch of Valsartan Tablets, USP in the U.S. Market.
The product is a therapeutic equivalent generic version of Diovan (valsartan) Tablets approved by the U.S. Food and Drug Administration (USFDA).
Valsartan is an angiotensin II receptor blocker (ARB) indicated for:
• Hypertension, to lower blood pressure in adults and children 6 years and older. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions
• Heart failure (NYHA class II to IV), to reduce hospitalization for heart failure in adults
• Post-myocardial infarction, for the reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction in adults.
The Diovan brand and generic market had U.S. sales of approximately $150 million MAT for the most recent twelve months ending in October 2021 according to IQVIA Health*.
Dr. Reddy's Valsartan Tablets, USP are available in 40 mg in bottle count size of 30, and 80 mg, 160 mg and 320 mg tablets in bottle count sizes of 90.
Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company headquartered in Hyderabad, Telangana, India. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.
Dr. Reddy's operates in markets across the globe. The company's major markets include - USA, India, Russia & CIS countries, and Europe.
